Two new drugs that e Press Trust of India while attending a symposium on transfusion associated hepatitis here.
Interferon-based therapy, however, works only in one-third of the cases, while about 70 percent of the patients do not benefit from it.
They are expected to have fewer side-effects compared to interferons that cause fever and lethargy.
The drugs have completed Phase I and Phase II trials for safety and efficacy, and are currently undergoing Phase III multi-centric trials in the United States, Europe and Southeast Asia.
The trials, being conducted by a team of 20 investigators, commenced a year ago and their results are expected to be out in 1997.
Experts are also working on an improved modified vaccine for hepatitis-B, Thomas said.